ASCO Genitourinary Cancers Symposium
ASCO GU 2022 PROpel Phase III Trial Highlights: Olaparib & Abiraterone vs. Placebo & Abiraterone as 1L Therapy for mCRPC
By
ASCO Genitourinary Cancers Symposium
FEATURING
Fred Saad
By
ASCO Genitourinary Cancers Symposium
FEATURING
Fred Saad
Login to view comments.
Click here to Login